Compare PTCT & MSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | MSM |
|---|---|---|
| Founded | 1998 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.0B |
| IPO Year | 2006 | 1996 |
| Metric | PTCT | MSM |
|---|---|---|
| Price | $76.82 | $125.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 6 |
| Target Price | $80.65 | ★ $96.20 |
| AVG Volume (30 Days) | ★ 1.5M | 847.3K |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 3.45% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ 3.12 |
| Revenue | $264,734,000.00 | ★ $3,363,817,000.00 |
| Revenue This Year | N/A | $5.82 |
| Revenue Next Year | $17.70 | $5.26 |
| P/E Ratio | ★ N/A | $40.33 |
| Revenue Growth | ★ 36.19 | 4.99 |
| 52 Week Low | $43.18 | $78.80 |
| 52 Week High | $90.87 | $128.79 |
| Indicator | PTCT | MSM |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 63.20 |
| Support Level | $74.45 | $82.07 |
| Resistance Level | $79.67 | $127.25 |
| Average True Range (ATR) | 3.27 | 2.93 |
| MACD | -1.01 | -0.04 |
| Stochastic Oscillator | 4.47 | 74.78 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.